(firstQuint)E2022 Patch Formulation Single Dose Phase I Study.

 This study is an open-label single site, randomized single dose study in 80 healthy Japanese male volunteers.

 The study consists of Period I to Period III, a total of 3 periods.

 In Period I, E2022 patches will be secured with seal.

 In Period II, single dose of E2022 5 mg tablet will be administered.

 In Period III, E2022 patches will be applied without seal.

 The features of the 5 patches will be evaluated in this study.

.

 E2022 Patch Formulation Single Dose Phase I Study@highlight

The purpose of this study is to evaluate the pharmacokinetics of a single dose of E2022 in healthy Japanese male volunteers.

